Personal essays and analysis on Ozempic, weight-loss drugs, and the culture they created. Published intermittently. Always cultural, never prescriptive. Subscribe to the monthly letter to get the next one in your inbox.
Not medical advice — a cultural conversation. Ozemback is not affiliated with any pharmaceutical company or healthcare provider.
The cultural shorthand started in late 2024. Patients report blunted cravings — for food, alcohol, shopping, gambling, even Instagram. The mechanism is real: GLP-1 receptors are densely expressed in reward circuits. Here is the honest cultural read on what is signal and what is anecdote.
Read the essay →Tirzepatide wins the scale by 6.5 points and it isn’t close. Semaglutide owns a placebo-controlled outcomes trial in 17,604 patients. Almost every version of this comparison drops one of those two facts.
Read more → Analysis · Market & pricingFor two years the gray-market discount ran roughly ten to one. In 2026 it’s closer to two to one — and the reason isn’t the crackdown. It’s the drugmakers cutting their own cash prices to kill the copycats.
Read more → Analysis · Market & pricing“Insurance coverage collapse” sounds national and sudden. It wasn't. It was a map forming — and the payers walking away are almost all the ones who write the check themselves.
Read more → Analysis · Market & pricingIt isn't stinginess and it isn't a billing glitch. A copay card is an acquisition weapon, and once supply, coverage, and a flat $499 cash channel all arrived, the job it was built to do was finished.
Read more → Analysis · Market & pricingMost coverage filed the $499 vial under good news for patients. It is a price floor Lilly chose, to undercut the compounders, route around the PBMs, and reprice the cash-pay market it now controls.
Read more → Analysis · Regulatory + policyEveryone is watching the FDA. But the agency that could turn a gray-market vial into a felony is the DEA — and the reason it has stayed out is the most revealing fact in the whole story.
Read more → Analysis · Regulatory + policyIn 2023 the FDA opened an investigation into GLP-1 medications and suicidal ideation. In 2026 it's technically still open. What the data actually shows — and why "unresolved" is doing a lot of work.
Read more → Analysis · Regulatory + policyThe story has changed tense. A year ago the question was whether Lilly's oral GLP-1 pill would work. Now it's when it ships — gated by the FDA clock, the label sequence, and factory capacity, not by biology.
Read more → Analysis · Regulatory + policyNot a ban — the expiration of a temporary legal exception written into a 1997 statute. Who actually lost: not the drugmakers, but the telehealth layer and the patients paying $199 instead of $1,999.
Read more → Analysis · Regulatory + policyThe 2026 FDA action closed a grey market that was never technically open. Understanding what changed — and what was always illegal — matters for understanding where this goes next.
Read more → Analysis · Clinical dataSELECT showed a 20% relative risk reduction in serious cardiac events. But the trial only enrolled patients with established CVD and no diabetes. Here is what the numbers actually say — and for whom.
Read more → Essay · NewFor a century the equation had two terms: diet and exercise. Then a generation woke up and the sentence had a third. An essay on what that third sentence does to a culture.
Read more →